Myriad Genetics, Inc.

Myrexis, Inc.

Scott Morham

Kenton Zavitz

Daniel Wettstein

Adrian Hobden

Gongping He

The present invention provides methods for preventing and treating HIV infection and AIDS by introducing cells displaying HIV late-domain phenotype into a patient, or by administering to a patient nucleic acids, polypeptides or small organic compounds to cause the formation of cells displaying HIV late-domain phenotype in the body of the patient.

Immunizing compositions comprising HIV-1 proviral constructs with an inactive p6 gag TSG101 UEV binding domain capable of producing budding-defective viral particles that remain tethered to the cell surface

Methods and pharmaceutical compositions for treating, and delaying the onset of, viral infection, are provided.

Method and composition for reducing expression of ROCK-II

Isolated protein complexes are provided comprising Tsg101 and HIV GAG or GAGp6. The protein complexes are useful in screening assays for selecting compounds effective in modulating the Tsg101-HIV GAG or GAGp6 interaction within the protein complexes.

TSG101-GAG interaction and use thereof

Isolated protein complexes are provided comprising Tsg101 and HIV GAGp6. The protein complexes are useful in screening assays for selecting compounds effective in modulating the Tsg101-HIV GAGp6 interaction within the protein complexes.

Tsg101-GAGp6 interaction and use thereof

Methods for inhibiting viral propagation and treating viral infection are provided which include administering to cells infected with viruses a therapeutic peptide or a derivative thereof.

Growing community of inventors

Salt Lake City, UT, United States of America

Scott Morham